| Mitchell Teruichi Godbee, MD | |
|
1125 Madison St, Jefferson City, MO 65101-5227 | |
| (573) 632-5265 | |
| (573) 632-5948 |
| Full Name | Mitchell Teruichi Godbee |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 22 Years |
| Location | 1125 Madison St, Jefferson City, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558455196 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 2005001988 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Capital Region Medical Center | Jefferson city, MO | Hospital |
| University Of Missouri Health Care | Columbia, MO | Hospital |
| Bothwell Regional Health Center | Sedalia, MO | Hospital |
| Lake Regional Health System | Osage beach, MO | Hospital |
| Ssm Health St Mary's Hospital Jefferson City | Jefferson city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Curators Of The University Of Missouri | 4486759560 | 959 |
| Capital Region Medical Center | 4688573686 | 168 |
News Archive
Stay tuned for the hottest science in the prevention of heart disease at ESC Preventive Cardiology 2021, an online scientific congress of the European Society of Cardiology.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
Over the last years, two teams of researchers at The Scripps Research Institute have steadily built a model of how a powerful DNA repair complex works. Now, their latest discovery provides revolutionary insights into the way the molecular motor inside the complex functions - findings they say may have implications for treatment of disorders ranging from cancer to cystic fibrosis.
› Verified 2 days ago
| Entity Name | Community Health Ctr Of Central Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538213244 PECOS PAC ID: 2062456015 Enrollment ID: O20050610000717 |
News Archive
Stay tuned for the hottest science in the prevention of heart disease at ESC Preventive Cardiology 2021, an online scientific congress of the European Society of Cardiology.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
Over the last years, two teams of researchers at The Scripps Research Institute have steadily built a model of how a powerful DNA repair complex works. Now, their latest discovery provides revolutionary insights into the way the molecular motor inside the complex functions - findings they say may have implications for treatment of disorders ranging from cancer to cystic fibrosis.
› Verified 2 days ago
| Entity Name | Capital Region Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477980837 PECOS PAC ID: 4688573686 Enrollment ID: O20070323000507 |
News Archive
Stay tuned for the hottest science in the prevention of heart disease at ESC Preventive Cardiology 2021, an online scientific congress of the European Society of Cardiology.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
Over the last years, two teams of researchers at The Scripps Research Institute have steadily built a model of how a powerful DNA repair complex works. Now, their latest discovery provides revolutionary insights into the way the molecular motor inside the complex functions - findings they say may have implications for treatment of disorders ranging from cancer to cystic fibrosis.
› Verified 2 days ago
| Entity Name | The Curators Of The University Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
Stay tuned for the hottest science in the prevention of heart disease at ESC Preventive Cardiology 2021, an online scientific congress of the European Society of Cardiology.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
Over the last years, two teams of researchers at The Scripps Research Institute have steadily built a model of how a powerful DNA repair complex works. Now, their latest discovery provides revolutionary insights into the way the molecular motor inside the complex functions - findings they say may have implications for treatment of disorders ranging from cancer to cystic fibrosis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mitchell Teruichi Godbee, MD Po Box 7687, Columbia, MO 65202 Ph: (573) 882-2259 | Mitchell Teruichi Godbee, MD 1125 Madison St, Jefferson City, MO 65101-5227 Ph: (573) 632-5265 |
News Archive
Stay tuned for the hottest science in the prevention of heart disease at ESC Preventive Cardiology 2021, an online scientific congress of the European Society of Cardiology.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
Over the last years, two teams of researchers at The Scripps Research Institute have steadily built a model of how a powerful DNA repair complex works. Now, their latest discovery provides revolutionary insights into the way the molecular motor inside the complex functions - findings they say may have implications for treatment of disorders ranging from cancer to cystic fibrosis.
› Verified 2 days ago
Dr. E. Dwain Roberts, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-556-7755 Fax: 573-761-3599 | |
Dr. Bonnie R Smith, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-556-7755 Fax: 573-761-3599 | |
Donald K Mcnutt, D.O. Radiology Medicare: Not Enrolled in Medicare Practice Location: 2713 Industrial Dr, Suite C, Jefferson City, MO 65109 Phone: 573-634-7884 Fax: 573-634-3146 | |
Dr. Jeffrey P. Patrick, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-556-7755 Fax: 573-761-3599 | |
Denzil J. Hawes-davis, D.O. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1125 Madison St, Jefferson City, MO 65101 Phone: 573-635-7141 Fax: 573-634-3146 | |
Dr. Steven C. Harper, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1241 W Stadium Blvd, Jefferson City, MO 65109 Phone: 573-556-7755 Fax: 573-761-3599 |